Revenue
2018
2019
2020
2021
2022
ALX ONCOLOGY HOLDINGS INC (ALXO)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | $1.2M | $4.8M | $2.1M |
| Research & development | $77.0M | $116.4M | $141.8M | $98.4M | $60.2M | $29.0M | $16.3M | $11.3M |
| Operating expenses | $104.0M | $142.5M | $170.3M | $127.4M | $83.6M | $44.8M | $24.0M | $15.8M |
| Operating income | −$104.0M | −$142.5M | −$170.3M | −$127.4M | −$83.6M | −$43.7M | −$19.2M | −$13.7M |
| EBITDAderived | −$103.3M | −$141.6M | −$169.4M | −$127.1M | −$83.5M | −$43.5M | −$18.8M | −$13.3M |
| Net income | −$101.7M | −$134.8M | −$160.8M | −$123.5M | −$83.5M | −$45.7M | −$19.2M | −$13.7M |
| Basic EPSper diluted share | -$1.90 | -$2.58 | -$3.74 | -$3.03 | -$2.07 | -$2.76 | -$7.56 | -$6.33 |
| Diluted EPSper diluted share | -$1.90 | -$2.58 | -$3.74 | -$3.03 | -$2.07 | -$2.76 | -$7.56 | -$6.33 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 19, 2026Form 4 | Lettmann JasonCHIEF EXECUTIVE OFFICER | SellCommon Stock | 12.3K | $2.17 | $26.7K | 293.6K |
| Mar 19, 2026Form 4 | Pinto ShellySVP, FINANCE AND CAO | SellCommon Stock | 903 | $2.17 | $2.0K | 86.8K |
| Feb 18, 2026Form 4 | Pinto ShellySVP, FINANCE AND CAO | SellCommon Stock | 565 | $2.27 | $1.3K | 87.7K |
| Feb 2, 2026Form 4 | GOODMAN COREY SDirector,TenPercentOwner | BuyCommon Stock · indirect | 3.18M | $1.57 | $5.00M | 8.45M |
| Jan 6, 2026Form 4 | Pinto ShellySVP, FINANCE AND CAO | SellCommon Stock | 3.9K | $1.11 | $4.4K | 88.3K |